Why insulin, the core element of diabetes treatment remains inaccessible for millions of people

Over a century after its discovery, insulin remains out of reach for millions. Published in The Conversation France, the piece explores how market concentration, policy inertia, and structural barriers continue to limit access. More than a diabetes issue, it reflects broader obstacles to essential medicine access.